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response, and three patients have maintained stable disease 
for more than 6 months.
Conclusions The 24-mg QD continuous dose of len-
vatinib was determined to be tolerable with encouraging 
anti-tumor activity in Japanese patients with solid tumors.
Keywords Lenvatinib · E7080 · Phase 1 · Angiogenesis · 
Japanese · Safety
Introduction
Angiogenesis, the formation of new blood vessels from a 
preexisting vascular network, is essential for tumor growth 
and metastasis [1, 2]. Vascular endothelial growth factor 
(VEGF) receptors 1–3 are expressed on endothelial cells 
and play essential roles in both physiologic and pathologic 
angiogenesis [3]. Lenvatinib is an oral inhibitor of multi-
ple receptor tyrosine kinases targeting VEGF receptors 
1–3, fibroblast growth factor (FGF) receptors 1–4, platelet-
derived growth factor receptor α, ret proto-oncogene, and 
v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene 
homolog (c-Kit) [4, 5]. In preclinical models, lenvatinib 
inhibits VEGF- and FGF-driven proliferation and tube for-
mation of human umbilical vein endothelial cells in vitro 
[6]. In vivo angiogenesis induced by overexpressed VEGF 
or FGF was significantly suppressed with oral lenvatinib 
treatments [6].
Phase 1 studies of lenvatinib have been conducted in 
patients with solid tumors exploring a wide range of dose 
levels and with different dosing schedules: once-daily 
(QD) continuous dosing in the European Union (EU) [7], 
twice-daily (BID) continuous dosing in the USA [8], and 
BID intermittent dosing (2 weeks on/1 week off) in Japan 
[9]. Based on clinical and pharmacokinetic (PK) data 
Abstract 
Purpose This phase 1 study aimed to assess the toler-
ability, safety, pharmacokinetics (PK), pharmacodynamics, 
and preliminary efficacy of lenvatinib capsules in Japanese 
patients with solid tumors when administered orally up to 
24 mg on a once-daily (QD) continuous schedule.
Methods Patients were enrolled in one of the two sequen-
tial cohorts (20 or 24 mg) of lenvatinib on a 28-day cycle 
based on the conventional 3 + 3 dose escalation design. 
Adverse events (AEs) were graded using the Common Ter-
minology Criteria for Adverse Events, version 4.0. Toler-
ability was judged based on dose-limiting toxicities (DLTs) 
during Cycle 1. The drug was defined as tolerable when the 
incidence of DLTs was less than 33 %.
Results  Nine patients received lenvatinib [20 mg (n = 3); 
24 mg (n = 6)]. No DLTs were observed. The most com-
mon AEs were thrombocytopenia, blood thyroid stimulat-
ing hormone increased, and hypertension (89 %), followed 
by leukopenia, headache, and proteinuria (78 %). The 
area under the concentration–time curve and maximum 
observed concentration increased dose proportionally. The 
PK profiles were similar to those in non-Japanese phase 1 
studies. One patient with leiomyosarcoma showed a partial 
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from these phase 1 studies, the recommended dose of len-
vatinib as a single agent has been determined to be 24-mg 
continuous QD dosing. Lenvatinib has shown encourag-
ing anti-tumor activity in phase 2 studies in patients with 
thyroid cancer [10], endometrial cancer [11], renal cancer 
[12], and non-squamous, non-small cell lung cancer [13]. 
Recently, lenvatinib demonstrated a significant improve-
ment in progression-free survival compared with placebo in 
patients with radioiodine-refractory differentiated thyroid 
cancer in a phase 3 study (SELECT study) and has recently 
been approved for this indication [14]. The toxicities in this 
study were manageable with dose modification and medi-
cal therapy. The most common adverse events (AEs) of any 
grade were hypertension, diarrhoea, fatigue or asthenia, 
decreased appetite, decreased weight, and nausea.
The previous phase 1 studies used a tablet formulation, 
although the final formulation for the phase 3 study was a 
capsule. A clinical pharmacology study with healthy vol-
unteers showed that dose modification is not necessary 
between the lenvatinib tablet and capsule formulation [15]. 
However, no phase 1 study of lenvatinib capsules in solid 
tumor patients has been reported. Furthermore, no PK or 
safety data for lenvatinib in Japanese patients with solid 
tumors have been reported when administered QD continu-
ously. Therefore, we conducted a dose escalation phase 1 
study of lenvatinib capsules up to 24 mg QD continuously 
in Japanese patients with advanced solid tumors.
Materials and methods
Patients
Eligible patients were aged 20 years or older with a cyto-
logically or histologically documented solid tumor that was 
refractory to standard therapy, or for which no standard 
therapy was available. Eligible patients also had completed 
anticancer therapy more than 4 weeks prior to lenvatinib 
treatment, and their toxicities had recovered to Grade 1 
or lower except for alopecia. Additional inclusion criteria 
were Eastern Cooperative Oncology Group performance 
status (ECOG PS) of 0–1, adequate bone marrow function 
(hemoglobin ≥9.0 g/dL, neutrophil count ≥1.5 × 103/μL, 
platelet count ≥10 × 104/μL), liver function (total bilirubin 
≤1.8 mg/dL, aspartate aminotransferase [AST] ≤100 IU/L, 
alanine aminotransferase [ALT] ≤100 IU/L), and renal 
function (creatinine ≤1.5 mg/dL or creatinine clearance 
≥50 mL/min). Patients were excluded from the study if 
they had brain metastasis that was symptomatic or required 
treatment, complication or history of interstitial pneumo-
nia, complication of pulmonary fibrosis with clinical symp-
toms, systemic infections requiring treatment, major cardi-
ovascular diseases (ischemic cardiac disease or arrhythmia, 
angina pectoris or myocardial infarction within 24 weeks 
prior to enrollment, or QTc greater than 480 ms), hemop-
tysis, hemorrhagic or thrombotic events within 4 weeks 
prior to enrollment, hypertension (systolic blood pressure 
≥150 mm Hg or diastolic blood pressure ≥90 mm Hg), or 
proteinuria (≥2+ in a qualitative test for urine protein or 
if ≥1+ proteinuria remained 2 days or more at ≥1.0 g for 
24 h accumulated), history of surgery that would influence 
absorption of the investigational drug, major surgery within 
4 weeks prior to enrollment, and coexisting effusion requir-
ing treatment. Patients were also excluded if they were una-
ble to take oral lenvatinib, were being treated with drugs 
that strongly inhibit or induce CYP3A4, or were positive 
for human immunodeficiency virus or hepatitis B or C 
virus.
Study design
This was a single-center, open-label, dose escalation phase 
1 study to assess the tolerability, safety, PK, pharmacody-
namics (PD), and preliminary efficacy of lenvatinib admin-
istered orally up to 24 mg QD on a continuous schedule 
in patients with solid tumors (clinicaltrials.gov identifier 
NCT01268293). This study was conducted in accordance 
with the Declaration of Helsinki and was approved by the 
institutional review board at the participating institution. 
Written informed consent was obtained from all patients 
before any study-related procedures were performed. The 
study used a conventional 3 + 3 dose escalation scheme. 
Patients were treated in sequential cohorts of escalat-
ing doses of lenvatinib administered in 28-day treatment 
cycles until disease progression, development of unaccep-
table toxicity, or withdrawal of consent. Planned lenvatinib 
doses were 20 and 24 mg. The 24-mg dose was the high-
est planned dose because prior phase 1 studies determined 
the recommended dose to be 24 mg QD. If no dose-limit-
ing toxicities (DLTs) were observed in three patients or if 
one DLT was observed in six patients at the 20-mg dose 
level, patient enrollment could be initiated for the 24-mg 
dose level. If zero or one DLT was observed in six patients 
at the 24-mg dose level, the dose was defined as tolerable. 
QD oral dose of lenvatinib was administered each morn-
ing regardless of food intake except for the day of blood 
sampling for PK analysis (Day 1 and Day 15 of Cycle 1) 
at which time lenvatinib was administered in a fasting con-
dition. Planned doses for dose reduction were 20, 14, and 
10 mg because 4 and 10 mg capsules were used. When a 
further dose reduction lower than 10 mg was necessary, the 
principal investigator and Eisai discussed the next dose on a 
case-by-case basis. If a DLT occurred, lenvatinib was inter-
rupted until recovered to Grade 0–1 or baseline and then 
restarted at a reduced dose. All subjects who demonstrated 
a DLT or completed Cycle 1 could continue treatment after 
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additional written informed consent for continuation in the 
study was obtained.
Safety
Safety assessments measured from baseline through 
30 days after the last dose included AE profile, laboratory 
variables [hematology, chemistry, urinalysis, thyroid-stim-
ulating hormone, free triiodothyronine (T3), free thyroxine 
(T4), human chorionic gonadotropin], vital signs (systolic 
and diastolic blood pressure, pulse rate, and body tem-
perature), weight, 12-lead electrocardiograms, ECOG PS, 
and physical examination. Toxicity was graded using the 
National Cancer Institute (Washington, DC, USA) Com-
mon Terminology Criteria for Adverse Events, version 
4.0. All AEs emerging during the study were classified by 
standardized medical terminology using the Medical Dic-
tionary for Regulatory Activities (MedDRA, version 15.1) 
and appropriately tabulated.
DLTs
DLTs were assessed during the first treatment cycle and 
were defined as Grade 4 neutropenia that persists for more 
than 7 days, Grade ≥3 febrile neutropenia with ≥38.5 °C 
and neutrophils <1.0 × 103/μL, Grade 4 thrombocyto-
penia or Grade 3 thrombocytopenia that requires blood 
transfusion, any Grade ≥3 non-hematologic toxicity 
(except for controlled hypertension, diarrhea/vomiting/
nausea controlled by supportive care, Grade ≥3 ALT, AST, 
γ-glutamyltransferase [γ-GTP], or alkaline phosphatase 
[ALP] increase that persists for ≤7 days, or other Grade 
≥3 abnormal clinical laboratory values that persist for 
≤3 days), or any toxicity that necessitates the interruption 
of lenvatinib for >7 days.
PK
Serial blood samples were collected at predose, 1, 2, 4, 8, 
and 24 h after the first dose on Day 1 of Cycle 1 and after 
repeated doses on Day 15 of Cycle 1. Blood samples at pre-
dose on Day 8 of Cycle 1 and Day 15 of Cycle 2 were also 
collected. Validated liquid chromatography/mass spectrom-
etry was used to determine lenvatinib in plasma.
PD
Blood samples for PD markers were collected on Days 1, 
8, and 15. Circulating endothelial cells (CECs) and circu-
lating endothelial progenitor cells (CEPs), which reflect 
active vascular turnover and angiogenesis, were measured 
as described previously [9]. Plasma samples were analyzed 
in triplicate for baseline and post-treatment levels of 10 
angiogenic proteins and cytokines using BioPlex PRO™ 
human group I cytokine 6-plex (VEGF, platelet-derived 
growth factor-BB, interleukin [IL]-6, IL-8, IL-10, and 
granulocyte colony-stimulating factor) and group II 3-plex 
(stem cell factor, stromal cell-derived factor-1α, and hepat-
ocyte growth factor [HGF]) panel assays (Bio-Rad Labora-
tories Inc.) and the Invitrogen™ FGF-basic singleplex bead 
kit (Life Technologies) by LSI Medience Corporation.
Efficacy
Efficacy was assessed using Response Evaluation Cri-
teria in Solid Tumors version 1.1, and assessments were 
conducted every 8 weeks or sooner if clinically indicated. 
Tumor response was defined as complete response (CR), 
partial response (PR), and stable disease (SD) defined as 
≥7 weeks after the start of treatment or progressive dis-
ease. Disease control rate was defined as the percentage of 




Nine patients (three patients in the 20-mg dose level and 
six patients in the 24-mg dose level) were enrolled at the 
National Cancer Center Hospital, Tokyo, Japan. Baseline 
characteristics are summarized in Table 1. The median 
age was 41 years (range 30–59), and seven patients were 
female. All patients had ECOG PS score of 0 at baseline. 
Eight patients had undergone two or more prior chemother-
apy regimens before enrollment in this study. Six patients 
had a primary diagnosis of leiomyosarcoma, one had endo-
metrial stromal sarcoma, one had colorectal cancer, and 
one had melanoma. The median duration of treatment with 
lenvatinib was 56 days (range 28–172) in the 20-mg dose 
level and 209 days (range 59–520) in the 24-mg dose level. 
The median percentage of the received dose of lenvatinib 
versus the planned dose was 97 % (range 77–100) in the 
20-mg dose level and 82 % (range 73–100) in the 24-mg 
dose level. Seven patients discontinued lenvatinib treatment 
due to progression of disease, one patient due to an AE, and 
one patient due to patient choice.
Safety and tolerability
No DLTs were reported in this study, and both the 
20- and 24-mg dose levels were judged to be toler-
able. The common AEs (≥30 % of patients in the 
total group) reported during the study are summarized 
in Table 2. The most frequently observed AEs were 
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thrombocytopenia, blood thyroid stimulating hormone 
increased, and hypertension (n = 8, 89 %), followed by 
leukopenia, headache, and proteinuria (n = 7, 78 %). 
There were no Grade 4 AEs. The observed Grade 3 
AEs were neutropenia (n = 3, 33 %), blood cholesterol 
increased (n = 2, 22 %), weight decreased, diarrhoea, 
hypertension, hypertriglyceridemia, leukopenia, ane-
mia, lymphopenia, and proteinuria (n = 1, 11 %). No 
patient died or had an AE that resulted in death on treat-
ment or within 30 days of the last dose. One serious 
AE, Grade 3 diarrhoea occurred in one patient in the 
24-mg dose level and was considered possibly related 
to the study drug by the investigator. The patient recov-
ered from this with supportive care and dose interrup-
tion. AEs leading to study drug withdrawal occurred 
in one patient (11 %) (Grade 1 arthralgia and Grade 2 
palmar-plantar erythrodysesthesia [PPE] syndrome) in 
the 24-mg dose level. AEs leading to study drug dose 
reduction occurred in two patients (22 %): one patient 
with Grade 3 proteinuria in the 20-mg dose level and 
one patient with Grade 2 stomatitis and Grade 2 oro-
pharyngeal pain in the 24-mg dose level. AEs leading to 
study drug interruption occurred in six patients (67 %): 
one patient in the 20-mg dose level and five patients in 
the 24-mg dose level. The most frequently occurring 
AEs leading to study drug interruption included pro-
teinuria (n = 3, 33 %), followed by hypothyroidism, 
abdominal pain upper, malaise, hypoalbuminemia, and 
edema peripheral (n = 2, 22 %).
PK
PK parameters of lenvatinib on Day 1 and Day 15 of Cycle 
1 are summarized in Table 3, and the mean plasma concen-
tration versus time profiles are shown in Fig. 1. Following 
oral administration, lenvatinib was absorbed rapidly, with a 
maximum concentration reached within 2 h.
The mean exposure, as measured by maximum observed 
concentration (Cmax) and area under the concentration–time 
curve (AUC), increased with an increasing dose of len-
vatinib. The mean accumulation index (Rac) of Cmax and 
AUC ranged from 1.27 to 1.42 and 1.32 to 1.44, respec-
tively. Plasma trough concentrations of lenvatinib on Day 
8, Day 15 of Cycle 1, and Day 15 of Cycle 2 remained at 
almost the same level, indicating that a steady state was 
attained with ~8 days of QD dosing (Fig. 2).
PD
At 15 days after lenvatinib treatment, the total number of 
CEPs was significantly decreased compared with base-
line levels (P < 0.01); this was attributable to a signifi-
cant decrease in the number of c-Kit (+) CEPs (P < 0.01; 
Fig. 3a). The total number of CECs remained unchanged 
(P > 0.05), but the number of c-Kit (+) CECs was 
decreased significantly (P < 0.01; Fig. 3b). Among plasma 
angiogenic factors and cytokines, VEGF increased signifi-
cantly (P < 0.01) on Day 15 compared with baseline levels 
(Fig. 3c, d).
Table 1  Patient characteristics Category 20 mg (n = 3) 24 mg (n = 6)
Age, years
 Median (range) 38 (32–59) 44 (30–59)
Sex, n (%)
 Male 0 2 (33)
 Female 3 (100) 4 (67)
Weight (kg)
 Median (range) 48 (44–48) 60 (53–66)
ECOG performance status, n (%)
 0 3 (100) 6 (100)
Type of primary tumor, n (%)
 Leiomyosarcoma 2 (67) 4 (67)
 Endometrial stromal sarcoma 1 (33) 0
 Colorectal 0 1 (17)
 Melanoma 0 1 (17)
Subjects with any previous anticancer surgical therapy, n (%) 3 (100) 6 (100)
Subjects with any previous radiotherapy, n (%) 1 (33) 1 (17)
Number of previous anticancer regimens, n (%)
 0 1 (33) 0
 1 0 0
 ≥2 2 (67) 6 (100)
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Efficacy
The BOR, duration of treatment, and maximum tumor 
shrinkage from baseline (%) for each patient are shown 
in Fig. 2. One patient with leiomyosarcoma in the 24-mg 
QD group had a BOR of PR with treatment duration of 
390 days. This gave the overall response rate of 11 %. Five 
patients had a BOR of SD. Of these, four patients had dura-
ble (≥23 weeks) SD: three patients with leiomyosarcoma 
and one patient with melanoma. The disease control rate 
(CR + PR + SD) was 67 %. Tumor shrinkage from base-
line was observed in five patients: one patient in the 20-mg 
dose level and four patients in the 24-mg dose level.
Discussion
This dose escalation phase 1 study showed that lenvatinib 
at 24 mg QD had a favorable safety profile for Japanese 
patients with solid tumors. Based on the absence of DLTs, 
the 24-mg dose of lenvatinib was determined to be toler-
able and recommended for further clinical studies in Japa-
nese patients with solid tumors.
The safety profile was similar to that of typical anti-angi-
ogenic agents. In particular, hypertension and proteinuria 
were common AEs. The safety profile of lenvatinib in Japa-
nese patients with solid tumors was similar to that observed 
in a non-Japanese phase 1 study [7, 8]. Hypertension was 
Table 2  Adverse events 
(any grades) with an overall 
incidence ≥30 %
MedDRA preferred term 20 mg (n = 3)  
n (%)
24 mg (n = 6)  
n (%)
Total (n = 9) 
n (%)
Any G G3 Any G G3 Any G G3
Any term 3 (100) 3 (100) 6 (100) 3 (50) 9 (100) 6 (67)
 Thrombocytopenia 2 (67) 0 6 (100) 0 8 (89) 0
 Hypertension 2 (67) 0 6 (100) 1 (17) 8 (89) 1 (11)
 Blood thyroid stimulating hormone increased 3 (100) 0 5 (83) 0 8 (89) 0
 Leukopenia 2 (67) 1 (33) 5 (83) 0 7 (78) 1 (11)
 Headache 3 (100) 0 4 (67) 0 7 (78) 0
 Proteinuria 2 (67) 1 (33) 5 (83) 0 7 (78) 1 (11)
 Aspartate aminotransferase increased 3 (100) 0 3 (50) 0 6 (67) 0
 Blood cholesterol increased 2 (67) 0 4 (67) 2 (33) 6 (67) 2 (22)
 Nausea 2 (67) 0 4 (67) 0 6 (67) 0
 Palmar-plantar erythrodysesthesia syndrome 2 (67) 0 4 (67) 0 6 (67) 0
 Malaise 2 (67) 0 4 (67) 0 6 (67) 0
 Hypertriglyceridemia 1 (33) 0 5 (83) 1 (17) 6 (67) 1 (11)
 Diarrhea 0 0 5 (83) 1 (17) 5 (56) 1 (11)
 Dysphonia 1 (33) 0 4 (67) 0 5 (56) 0
 Arthralgia 1 (33) 0 4 (67) 0 5 (56) 0
 Myalgia 0 0 5 (83) 0 5 (56) 0
 Neutropenia 2 (67) 2 (67) 3 (50) 1 (17) 5 (56) 3 (33)
 Alanine aminotransferase increased 3 (100) 0 2 (33) 0 5 (56) 0
 Blood lactate dehydrogenase increased 2 (67) 0 2 (33) 0 4 (44) 0
 Electrocardiogram T wave inversion 0 0 4 (67) 0 4 (44) 0
 Abdominal discomfort 1 (33) 0 3 (50) 0 4 (44) 0
 Rash 1 (33) 0 3 (50) 0 4 (44) 0
 Edema peripheral 2 (67) 0 2 (33) 0 4 (44) 0
 Decreased appetite 0 0 4 (67) 0 4 (44) 0
 Hypoalbuminemia 2 (67) 0 2 (33) 0 4 (44) 0
 Oropharyngeal pain 1 (33) 0 3 (50) 0 4 (44) 0
 Blood alkaline phosphatase increased 0 0 3 (50) 0 3 (33) 0
 Abdominal pain upper 0 0 3 (50) 0 3 (33) 0
 Vomiting 2 (67) 0 1 (17) 0 3 (33) 0
 Hematuria 3 (100) 0 0 0 3 (33) 0
 Hyperthyroidism 1 (33) 0 2 (33) 0 3 (33) 0
 Hypothyroidism 0 0 3 (50) 0 3 (33) 0
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well managed by antihypertensive agents without serious 
AE, and proteinuria was managed by dose interruption and 
reduction. In this study, thrombocytopenia was reported 
as the most frequently observed AE. In the previous phase 
1 study in Japan, DLTs were reported in two patients at 
the 20-mg BID dose levels, both of whom experienced a 
Grade 3 platelet count decrease [9]. This may be due to the 
high exposure of lenvatinib (40 mg/day), because Grade 3 
thrombocytopenia was not observed in this study. However, 
platelets should be carefully monitored in clinical practice 
in case of severe thrombocytopenia. Although PPE syn-
dromes in this study were generally mild with no Grade 
3, one patient discontinued the study drug due to Grade 2 
PPE syndrome. Three patients showed Grade 2 PPE in this 
study; the onset of Grade 2 PPE in these patients was 50, 
71, and 281 days after initiating lenvatinib treatment, sug-
gesting that a certain period of treatment with lenvatinib 
can cause Grade 2 PPE. Education about early signs and 
symptoms of PPE for patients may be important to prevent 
and manage PPE syndromes.
PK parameters, including Cmax and AUC, increased in a 
dose-dependent manner. Mean maximum concentration at 
steady state (Css,max) and area under the concentration–time 
curve over the dosing interval on multiple dosing (AUC(0-τ)) 
after multiple doses in the 24-mg dose level by capsule 
in this study were 518 ng/ml and 4140 ng h/mL, respec-
tively. In the previous phase 1 study in the EU, 24 patients 
received a 25-mg QD dose of lenvatinib by tablet, and 
the median Css,max and AUC(0-τ) after multiple doses were 
545 ng/ml and 4220 ng h/mL. A clinical pharmacology 
study was conducted to evaluate the effect of formulation 
on the PK of lenvatinib, and this study showed that the cap-
sule formulation produces slightly lower exposure (~10 to 
14 %) to lenvatinib compared with tablet formulation [15]. 
These data demonstrated that the PK profile in Japanese 
patients is similar to that observed in the EU study.
The subpopulation of CECs and CEPs may be predictive 
of disease or clinical responsiveness to anti-VEGF agents 
[18]. Lenvatinib reduced the number of CEPs but not CECs. 
Specifically, c-Kit (+) CEPs were reduced much more than 
c-Kit (−) CEPs, suggesting that Kit kinase inhibition by 
lenvatinib contributes to the total CEP reduction. Changes 
in the levels of plasma proteins may reflect the biologic 
Table 3  Pharmacokinetic parameters of lenvatinib following a single 
dose (Cycle 1, Day 1) and multiple doses (Cycle 1, Day 15)
AUC(0–24h), area under the concentration–time curve from zero time 
to 24 h; AUC(0-τ), area under the concentration–time curve over the 
dosing interval on multiple dosing; Cmax, maximum observed con-
centration; Css,max, maximum observed concentration at steady state; 
CLss/F, oral clearance at steady state; tmax, time at which the high-
est drug concentration occurs; Rac, accumulation index; tss,max, time at 
which the highest drug concentration occurs at steady state; t1/2, ter-
minal elimination phase half-life
Rac (Cmax) = Css,max/Cmax, Rac (AUC) = AUC(0-τ)/AUC(0–24h)
Data are the mean ± standard deviation except tmax and tss,max; for 
tmax and tss,max, median (minimum–maximum) is shown
a n = 4
b n = 5
c n = 4
20 mg (n = 3) 24 mg (n = 6)
Cycle 1, Day 1
 Cmax (ng/mL) 309 ± 60.1 418 ± 167
 tmax (h) 2.0 (2.0, 2.0) 2.0 (2.0, 4.0)
 AUC(0–24 h) (ng h/mL) 2500 ± 647 3150 ± 352a
Cycle 1, Day 15
 Css,max (ng/mL) 415 ± 267 518 ± 209
 tss,max (h) 2.0 (2.0, 2.1) 2.0 (2.0, 4.0)
 AUC(0-τ) (ng h/mL) 3690 ± 1790 4140 ± 1350b
 CLss/F (L/h) 6.17 ± 2.34 6.19 ± 1.53b
 Rac (Cmax) 1.27 ± 0.562 1.42 ± 0.708

























































Fig. 1  Plasma concentration versus time profile of lenvatinib follow-
ing a single dose (Cycle 1, Day 1) and multiple doses (Cycle 1, Day 
15)
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Fig. 2  Treatment duration and 












































































































Fig. 3  Change in the number of CEPs (a), CECs (b), and the levels of biomarkers (c and d) from predose baseline to Day 15. P values were cal-
culated using the Wilcoxon signed-rank test
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response of host tissues to therapy and may be useful 
markers for the clinical activity of anti-tumor agents. The 
inhibitory effect of lenvatinib on VEGF signaling has been 
evaluated in preclinical studies; VEGF-induced growth of 
human endothelial cells is suppressed by lenvatinib [18]. 
The increasing VEGF level in this study suggested that len-
vatinib inhibited the VEGF signaling pathway. No correla-
tion between the clinical outcome and biomarkers in this 
study can be assessed due to the small number of patients.
Although efficacy was not a primary objective, encour-
aging preliminary evidence of anti-tumor activity was 
observed in Japanese patients with solid tumors. Tumor 
shrinkage from baseline was observed in five patients, rang-
ing from −14.9 to −37.1 %. Interestingly, tumor shrinkage 
was observed in four patients with leiomyosarcoma, includ-
ing one patient achieving PR. A large number of drugs have 
failed to provide PR or tumor shrinkage in patients with 
sarcoma [16]. Even pazopanib, a recently approved molec-
ular target agent in patients with sarcoma, showed the best 
overall response of PR in only 6 % of patients in a phase 
3 study [17]. This fact suggests that lenvatinib could be an 
effective drug that induces tumor shrinkage in patients with 
solid tumors including leiomyosarcomas. This study also 
indicated that lenvatinib could be administered for a long 
term. The median duration of treatment with lenvatinib was 
209 days in the 24-mg dose level, and two patients achieved 
treatment duration of more than 1 year. This may be due to 
the effective disease control and manageable safety profile 
with dose modification and medical therapy.
In conclusion, lenvatinib was tolerated up to a dose of 
24 mg QD in Japanese patients with solid tumors in this 
study. The safety and PK profiles of lenvatinib were simi-
lar to those observed in non-Japanese populations. AEs in 
this study were generally manageable with dose modifica-
tion and medical therapy. Encouraging anti-tumor activity 
of lenvatinib supports further development of lenvatinib for 
the treatment of patients with a wide range of solid tumors.
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